TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 62.8nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 202nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 277nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from dual VBC E3 ligase (unknown origin) te...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 418nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 418nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 422nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 795nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 800nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 800nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
Affinity DataIC50: 882nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from VBC E3 ligase (unknown origin) binary ...More data for this Ligand-Target Pair
Affinity DataIC50: 888nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from VBC E3 ligase (unknown origin) binary ...More data for this Ligand-Target Pair
Affinity DataIC50: 900nMAssay Description:Displacement of FAM-DEALAHyp-YIPD from VHL/elongins-B/elonginC (unknown origin) by fluorescence polarization assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.04E+3nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from VBC E3 ligase (unknown origin) binary ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.14E+3nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from VBC E3 ligase (unknown origin) binary ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.21E+3nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from VBC E3 ligase (unknown origin) binary ...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.62E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.28E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.96E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 3.02E+3nMAssay Description:Displacement of (2S,4R)-N-(4-bromobenzyl)-4-hydroxy-1-(3,3,3-trifluoropropanoyl)pyrrolidine-2-carboxamide from VBC E3 ligase (unknown origin) binary ...More data for this Ligand-Target Pair
Affinity DataIC50: 4.10E+3nMAssay Description:Displacement of FAM-DEALAHyp-YIPD from 6xHis-tagged VHL (1 to 213)/elongins-B/elonginC (unknown origin) expressed in Escherichia coli BL21 after 1 mi...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.35E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.68E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 4.90E+3nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.97E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.39E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 5.50E+3nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.17E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.25E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.25E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.30E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.73E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 9.32E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 9.90E+3nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.10E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 1.60E+4nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.67E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.69E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.73E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.75E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.76E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.96E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.99E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.06E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.33E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.41E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C/Hypoxia-inducible factor 1-alpha/von Hippel-Lindau disease tumor suppressor(Homo sapiens (Human))
Arvinas
Curated by ChEMBL
Arvinas
Curated by ChEMBL
Affinity DataIC50: 2.50E+4nMAssay Description:Inhibition of His-tagged VHL/elongin B/elongin C (unknown origin) interaction with HIF1alpha preincubated for 10 mins followed by fluorescin labelled...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.04E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.14E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.29E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair